Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. Through its fully
integrated research and development operations the company focuses on the
development of innovative antibiotics, antifungals and oncology drugs, targeting the
medical challenge of resistance and non-response to current treatment options.
Key facilities and infrastructure: Basilea’s research emphasis is placed on focused optimization of successful compound classes addressing established targets (e.g. beta-lactams) as well as pursuing novel targets through the discovery of drug leads by screening of compound libraries and structure-based drug design.
The discovery of new medicines is supported by state-of-the-art technologies integrating the areas of genomics, enzyme kinetics, assay development, screening, cell biology, medicinal chemistry, crystallography, modeling and pharmacology. The project teams in Basel work closely together with scientists in Basilea China on the search for novel molecules that have distinct advantages over available therapies.
Contact: Dr. Jürg Dreier